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Finding the most rigorous, updated, and well received 
clinical evidence is a crucial and challenging task in 
the practice of Evidence-Based Medicine (EBM). In 
this article, we describe a knowledge domain 
visualization-based quantitative approach that is 
designed to support the task of searching for high-
quality clinical evidence in the medical literature. We 
illustrate the use of this new approach with the 
knowledge domain of Non-Steroidal Anti-Inflammatory 
Drugs (NSAIDs). A sample of the literature is 
visualized in a base map depicting structural and 
temporal properties of emerging themes and references 
made by such themes over time. In addition, the 
visualization highlights the rigorousness of a published 
clinical trial in terms of the type of study design 
retrieved dynamically from PubMed. The contribution 
of this approach is that it offers users an integrated 
search environment so that the rigorousness, 
recentness, and consensus of clinical evidence can be 
assessed with the support of visual exploration 
facilities. 
1. Introduction 
In September 2004, Merck & Co. announced an 
immediate worldwide withdrawal of its best-selling 
arthritis drug Vioxx after a three-year colon cancer 
clinical trial revealed an increased risk of heart attacks 
18 months after patients started taking the drug [1]. It 
was estimated that Merck's Vioxx liability could reach 
$38 billion.  
This withdrawal has prompted researchers to re-
examine the biomedical literature in order to establish 
whether available clinical evidence might have led to 
the withdrawal sooner. Many patients are now 
wondering what would be the best alternative for them 
[2]. Is there a consensus in the medical literature? 
What is the big picture of all the available evidence? 
Evidence-Based Medicine (EBM) emphasizes the 
fundamental role of rigorous evidence in making 
clinical decisions and training [3]. The most rigorous 
types of evidence include randomized controlled trials 
(RCTs), systematic reviews (SRs), and meta-analyses 
because of the least amount of biases in these types of 
evidence. The general practice of EBM typically 
follows a 5-step procedure [4, 5]: 
1. Identify clinical questions, 
2. Search for the best external evidence, 
3. Clinically appraise the validity and importance of 
the evidence, 
4. Put it into clinical practice, and 
5. Evaluate the performance. 
In this article, we focus on the second step, i.e. 
searching for the best evidence. In addition, we also 
address the role of clinical evidence in understanding 
the evolution of a pharmacological field, which is 
intrinsically evidence-based medicine. The goal of the 
study is to identify the special needs from the 
perspective of evidence-based medicine and how 
knowledge domain visualization can facilitate some of 
the tasks. 
Searching for the best evidence is a critical 
component of EBM. The complexity of the task is 
largely due to three factors: 1) the overwhelming size 
of the search space, 2) the time-critical nature of 
clinical evidence, and 3) the evasive context to assess 
the perceived value of specific evidence. The number 
of medical publications indexed in Medline, for 
example, has been growing by hundreds of thousands 
each year. The size of a search space of RCTs along 
would be still too large. We will give a concrete 
example of the size problem in subsequent sections of 
this article. The time-critical nature implies that we 
need to find not only the most rigorous evidence, but 
also the most recent and the most valuable ones as 
perceived by others in the field. 
We propose an approach that could potentially 
compliment conventional search methods with a 
reduced complexity and reduced costs. In addition to 
using the type of study design as a search criterion for 
high-quality evidence, we propose that the citations of 
a clinical trial article can be used as an additional 
indicator of quality. Furthermore, we believe that the 
position of such articles in networks of other evidence 
and other articles is also a potentially valuable clue of 
quality.  
The rest of the article is organized as follows. We 
explain the motivations of our work and introduce the 
basic concepts and techniques. We describe the 
implementation of the new method and discussed the 
findings of preliminary results with reference to 
existing approaches. The scope of underlying 
assumptions and their limitations are discussed. 
Finally, we identify challenging issues to be addressed. 
2. Background 
2.1. The Strength of Clinical Evidence 
In EBM, the quality of clinical evidence is 
measured by its strength, primarily in terms of its 
methodological rigorous. A number of widely known 
classification schemes are outlined below.  
Oxford Centre for EBM recommends five levels of 
evidence, from level 1 (the strongest) to level 5 (the 
weakest). SRs with homogeneity of RCTs are 
classified at level 1a. RCTs with a narrow confidence 
interval are the second best (level 1b).  
National Cancer Institute [6] regards randomized, 
double-blinded controlled clinical trials as the gold 
standard, i.e. the best evidence. However, it does not 
give meta-analysis a higher status than randomized 
studies because of various known weaknesses of meta-
analysis [7, 8].  
A highly regarded source of evidence is the 
systematic reviews prepared and maintained by the 
Cochrane Collaboration [9, 10]. Cochrane reviews’ 
reputation is partly drawn from their regular updates 
and revisions. Medline, through its web-based interface 
PubMed, is probably the most widely used source of 
evidence. A Medline record contains a publication type 
field to index the type of study design, including 
randomized controlled clinical trial, clinical trial, and 
meta-analysis. The provision of the publication type 
[pt] makes it possible to search for RCTs related to a 
given topic. 
In a recent study of general thoracic surgery, the 
publication type in Medline records was used to 
identify meta-analysis and RCTs [5]. They followed 
the strategy described in [11] by searching for meta-
analysis in the publication type field. Similarly, the 
publication type was also used for searching for RCTs.  
Selection criteria based on study types are widely 
used. However, the task could be further simplified by 
taking into additional criteria. 
2.2. Additional Criteria of Quality 
A potentially effective criterion for high-quality 
evidence is how frequently a clinical trial article or a 
meta-analysis article has been referenced by 
subsequent studies of others. The assumption is that 
clinical evidence reported in a highly cited article tends 
to be more important than one in a less frequently cited 
article. We acknowledge that articles can be cited for 
many reasons, including both positive and negative 
citations. The rational of our assumption is, regardless 
of varying citation motivations, if an article has drawn 
sufficient attention, then it in effect has a place in the 
knowledge structure.  
The citation-based quality indicator is derived from 
citation analysis of scientific literature. The widely 
known source of scientific citations is the Science 
Citation Index (SCI) maintained by the Institute for 
Scientific Information (ISI).  
Citation counts of articles can be seen as the first-
order measurements of the perceived values of these 
articles. One could compile a list of evidence along 
with citation counts to corresponding articles. 
However, such lists do not reveal salient relationships 
between clinical trials. From such lists, we would only 
know that two clinical trials are highly cited, but we 
have no way to tell whether the two have ever been 
considered together and, if so, how frequently. 
Co-citations are higher-order relationships that can 
reveal more insights into a broader context of an 
article’s role in a knowledge domain. Co-citations are 
instances in which two articles are referenced together 
in subsequently published articles [12, 13].  
2.3. Visualizing Emerging Trends 
CiteSpace is a series of design, implementation, 
and refinement efforts [14-17]. Its primary goal is to 
enable users visually identify emerging trends and 
transient patterns in scientific literature. CiteSpace 
visualizes the evolution of citation and co-citation 
patterns associated with a knowledge domain over 
time.  
CiteSpace is built on two basic concepts: research 
fronts and intellectual bases [17]. A research front is 
defined as a cluster of topical terms that have a sharp 
increase in their usage. A detected sharp increase is 
called a burst. Therefore, these terms are called burst 
terms. A research fronts corresponds to an intellectual 
base.  
We used CiteSpace in a number of domain 
visualization studies of paradigm shift and abrupt 
changes, including the superstring revolutions in 
physics, the mass extinction debates, and emerging 
trends in research of terrorist events. However, we 
have not applied the approach to a domain like EBM, 
where it is essential to understand the consensus 
concerning available evidence and how the consensus 
changes in light of new evidence. To our knowledge, 
we are not aware of visual exploration tools designed 
for searching specific types of evidence in the context 
of their home domain. We propose a conceptual 
framework to extend the knowledge domain 
visualization techniques to support evidence search 
tasks in EBM. 
3. Conceptual Framework 
The conceptual framework aims to facilitate the 
search for the best evidence in the medical literature by 
simplifying the assessment process concerning the 
rigorous, recentness, and consensus of evidence in a 
visual exploration environment. In this article, we 
focus on integrating various cues that can be retrieved 
from PubMed and the Web of Science. The framework 
can be extended to incorporate additional sources. 
A practical issue is that although PubMed is openly 
accessible, the Web of Science is subscription-based 
and it does not permit programmatic access. As the 
first step towards supporting EBM, we design and 
implement the following method to easy this problem. 
Suppose our aim is to locate the best evidence 
regarding lung cancer treatments. The procedure is as 
follows: 
1. Search for articles in the Web of Science on lung 
cancer (the search is intentionally broad). 
2. Visualize the search results in CiteSpace, 
including emerging trends and temporal patterns. 
3. Automatically annotated articles with specified 
publication types, namely meta-analysis, 
randomized controlled clinical trial, and clinical 
trial. 
4. Explore the visualization map and select articles 
for critical appraisals. 
5. (Repeat the procedure periodically or as needed).  
 In our current implementation, the automated 
annotation is made possible by retrieving the 
publication type information from PubMed 
simultaneously as the system layouts the network. The 
major advantage of this method is its non-intrusive 
nature. The only way the user can tell the behind-the-
scene search is when an increasing number of articles 
are annotated with publication types retrieved from 
PubMed. Because the additional search is so cost-
effective and efficient, the user does not even have to 
save the information locally. 
Given the assumption that highly cited clinical 
evidence tends to be the strongest evidence, we focus 
on several types of relationships between high-quality 
evidence and its first- and second-order properties in 
bibliographic networks. By visualizing various 
structural and temporal properties of such 
relationships, we expect that our method can provide a 
useful tool for EBM practitioners to find the best 
evidence with improved efficiency. 
We expect that the best evidence should 
demonstrate unique features in the visualizations of 
associative networks of articles and topic terms. For 
example, evidence reported in highly cited publications 
tends to be more valuable than evidence in less 
frequently cited publications. Evidence appears as hubs 
of co-citation clusters of articles should be more 
significant than peripheral ones. We expect to find 
Meta-analysis as a hub more often than other types of 
studies.  
In the new visualization, the publication type of 
three types of EBM evidence are marked as ‘r’ for 
randomized controlled clinical trial, ‘c’ for clinical 
trial, and ‘m’ for meta-analysis. PubMed allows both 
‘r’ and ‘c’ to be assigned to the same article, hence we 
may see articles marked with rc’s in the map. 
According to the general consensus in EBM, articles 
marked with r’s or m’s are top-level evidence. In 
addition, rc’s and m’s with unique topological 
properties in co-citation networks visualized by 
CiteSpace should be particularly important, including 
positions such as hubs and bridges as well as visual 
attributes such as the size of citation tree rings. 
4. Case Study 
We illustrate the approach with an analysis of 
clinical evidence in the literature of Non-steroidal 
Anti-inflammatory Drug, or NSAID (1990-2004). 
NSAID has a complex history and it is also involved in 
recent headline news. More importantly, it is a topic 
that will continue to evolve. Note that the following 
background information regarding NSAID was based 
on a study of the resultant visualizations and a limited 
number of follow-up searches guided by these 
visualizations, but we present them earlier so that it 
gives the reader a meaningful context. 
4.1. NSAID 
The goal of research in NSAIDs is twofold: 
improving the effectiveness of anti-inflammatory drugs 
and reducing adverse side-effects [18]. Vioxx is a 
member of a family of drugs called Cox-2 selective 
inhibitors [19]. Cox-2 selective inhibitors were 
originally introduced as a replacement of an earlier 
generation of drugs known as non-selective inhibitors, 
which indiscriminately suppress cyclooxygenase-1 
(COX-1) and cyclooxygenase-2 (COX-2). However, 
one of the major adverse effects of inhibiting COX-1 is 
the lower stomach prostaglandin levels, which in turn 
may cause stomach ulcers and internal bleeding. 
Compared with non-selective inhibitors, selective 
inhibitors of COX-2 do not upset the stomach as much 
as their earlier counterparts. 
Both proton pump inhibitors and histamine H2-
receptor blockers can be used to suppress gastric acid. 
Proton pump inhibitors were found to be more 
effective. More importantly, proton pump inhibitors 
have minimal side effects and few significant drug 
interactions, and they are generally considered safe for 
long-term treatment. Therefore, proton pump inhibitors 
are often given as co-prescriptions of non-selective 
inhibitors. We will return to this topic when we discuss 
the visualizations. 
NSAIDs are widely used not only for their anti-
inflammatory, but also analgesic, antipyretic, and (as in 
case of aspirin) anti-coagulating activity. Studies 
suggest that NSAIDs prevent colorectal cancer and 
may protect against the development of Alzheimer's 
disease. As it was later reported in the mass media on 
December 22, 2004, the same colon cancer clinical 
trial that led to the Vioxx withdraw found that Vioxx 
prevented precancerous colon polyps in some patents. 
4.2. Data Collection 
Bibliographic records were retrieved from the Web 
of Science using a search query of (NSAID or (Non-
steroidal Anti-inflammatory Drug)). We use the 
systematic review and meta-analysis [20] as our gold 
standard. The NSAID dataset consists of 4,921 records. 
Among them, 3,514 records have cited references. 
These records are known as citing records. 
Visualizations represent references cited by these 
records. Citing records are included if themselves are 
cited by others. 
CiteSpace imports datasets directly and selects the 
terms of up to four consecutive words from titles, 
abstracts, and descriptors of citing records. The 
subsequent analysis includes burst terms only, which 
are terms with sharply increased frequencies over time. 
CiteSpace divides the entire time interval into a 
number of sub-intervals, or time slices. A snapshot 
network is derived for each time slice. The resultant 
time series of networks are subsequently merged into a 
global network. Technical details of the algorithms are 
described in [14, 17] 
CiteSpace supports two visualization views: cluster 
views and timezone views. Cluster views show 
networks as the commonly seen types of node-and-link 
diagrams, whereas timezone views arrange articles and 
terms in correspondence to the time of their publication 
or their peak time. 
5. Results 
5.1. The Profile of the NSAID Literature 
Figure 1 depicts the volume of annual publications 
in NSAID. Articles at Level 0 were cited once or more 
within the sample of 3,512 articles retrieved from the 
Web of Science. Articles at Level 3 were cited three 
times or more. Articles at Level 5 were cited five times 
or more. It is clear that Level 5 articles are 
exceptionally rare in comparison to the vast volume of 
less frequently cited articles. Visualizations generated 
by CiteSpace typically feature the thin layers only – the 
cream of the crop – rather than the entire sample.  
 
Figure 1. The cream of the crop by citations.  
 
Figure 2. The proportions of various types of 
Level 3 and Level 5 clinical trial articles in the 
NSAID literature. 
Figure 2 shows the proportions of various types of 
evidence in the NSAID literature. The average 
percentage of RCTs among Level 5 and Level 3 
articles is 16.6% and 12.2%, respectively. The average 
percentage of Meta-analysis among Level 5 and Level 
3 articles is 2.3% and 1.5%. These figures suggest that 
evidence papers tend to be cited more often than other 
types of papers. 
 
5.2. Cluster Views and Time-zone Views 
CiteSpace supports two types of visualizations: 
cluster views and time-zone views. Cluster views 
visualize a network as a patchwork of a series of 
snapshot networks taken in consecutive time intervals 
known as time slices. Common nodes between 
networks in adjacent time slices are shared in the 
merged network.  
Time-zone views are generated based on a 
modified force-directed placement algorithm such that 
nodes are placed in a series of parallel strips known as 
time zones. CiteSpace also supports visualizations in 
grayscale as well as visualizations in full color to 
depict temporal patterns. The tree-ring like circle 
surrounding a node represents the citation history of 
the underlying article. The history progresses from the 
center outwardly.  
The type of clinical evidence is marked as rc, c, or 
m. The position of an evidence node and the size of its 
citation tree ring can be used as additional search 
criteria by an EBM practitioner. 
Figure 3 shows an example of the visualization of 
clinical evidence in the literature of NSAID (1995-
2005), including four RCTs in unique positions in 
terms of the network topology and one meta-analysis 
in a similar position. In essence, papers in such 
positions have high betweenness centrality, which 
measures how often an arbitrarily chosen shortest path 
in the network goes through such nodes. 
 
 
Figure 3. RCTs (rc) and meta-analysis (m) available in a synthesized network visualization of the 
NSAID literature (1995-2005) (Nodes=399, Links=734). Articles in this visualization must have at 
least 6 citations. Clinical evidence at strategic positions (in terms of high centrality) is marked by 
arrowed lines. The sharply increased use of the term proton pump inhibitor is identified. 
In CiteSpace visualizations, a line between a term 
and an article denotes that the article is cited by the 
hosting article of the term. The colors of lines are time-
stamped with earlier connections in blue and the latest 
in red. The nature of each cluster can be identified by 
the most prominent term associated with it.  
In CiteSpace, one can use a function called 
marquee selection to select and analyze a cluster of 
nodes by dragging a rectangle area around nodes of 
interest. Figure 4 shows five clusters selected in such 
way. For example, the left-most cluster of 19 nodes is 
about Alzheimer’s disease in relation to NSAID. The 
upper right cluster of 65 nodes is about selective cox-2 
inhibitor. 
The overall colors of a cluster indicate its age, 
either as an emerging one or a long established one. 
The Alzheimer’s disease cluster in Figure 4 has many 
light-colored lines, suggesting its relatively young age. 
Similarly, the selective cox2 inhibitor cluster is also 
relatively young. There are three clusters in the center 
of the cluster view. We refer them as the upper center, 
the lower center, and the cluster on the right. The upper 
center cluster contains 160 nodes, including both 
articles and terms. It is a long established cluster, 
containing terms such as H2-receptor. The lower center 
cluster is much recent, containing terms such as proton 
pump inhibitor and non-selective NSAIDs.  
 
Figure 4 Five clusters selected in a network 
visualization of the NSAID literature (1990-
2004) (Nodes = 499, Links =2,018). The number 
at the corner of each selected area is the 
number of nodes included. 
Table 1 lists the most frequently found Medical 
Subject Heading (MeSH) terms in the five clusters. 
Based on the MeSH terms, the five clusters are 
identified as the Alzheimer’s diseases cluster, the 
Cyclooxygenase cluster, the colon cancer cluster, the 
adverse effects of selective inhibitors cluster, and the 
adverse effects of non-selective inhibitors cluster. The 
visualization provides an alternative way to locate 
high-quality evidence. For example, amount the 19 
nodes in the Alzheimer’s disease cluster, there is a 
highly cited meta analysis [21], which was cited 43 
times in the dataset. 
Table 1. Top-5 MeSH terms assigned to the 
five selected clusters shown in Figure 4. 
19 CLUSTER: Alzheimer Disease  
14 Anti-Inflammatory Agents, Non-
Steroidal/*therapeutic use 
10 Alzheimer Disease/*epidemiology 
8 Alzheimer Disease/*prevention & control 
8 Alzheimer Disease/*drug therapy 
6 Alzheimer Disease/*pathology 
  
56 CLUSTER: Cyclooxygenase 
28 Anti-Inflammatory Agents, Non-
Steroidal/*pharmacology 










65 CLUSTER: Colonic Neoplasms 
22 Anti-Inflammatory Agents, Non-
Steroidal/*pharmacology 
20 Colonic Neoplasms/*prevention & control 
18 Apoptosis/*drug effects 
16 Aspirin/*therapeutic use 
14 Anti-Inflammatory Agents, Non-
Steroidal/*therapeutic use 
  
103 CLUSTER: Adverse Effects of Selective 
Inhibitors  
46 Anti-Inflammatory Agents, Non-
Steroidal/*adverse effects 
34 Cyclooxygenase Inhibitors/*therapeutic use 
34 Anti-Inflammatory Agents, Non-
Steroidal/*therapeutic use 
24 Cyclooxygenase Inhibitors/*pharmacology 
22 Isoenzymes/*antagonists & inhibitors 
  
160 CLUSTER: Adverse Effects of 
Traditional, Non-selective Inhibitors 
160 Anti-Inflammatory Agents, Non-
Steroidal/*adverse effects 
42 Gastrointestinal Hemorrhage/*chemically 
induced 
36 Aspirin/*adverse effects 
28 Gastrointestinal Diseases/*chemically 
induced 
26 Peptic Ulcer/*chemically induced 
24 Helicobacter pylori 
 
Figure 5 shows a time-zone view of the evolution 
of NSAID. The visualization contains two types of 
entities: cited articles, and citing terms. The 
distributions of various types of clinical evidence are 
marked in terms of their study design types. For 
example, the 1991 article by Gabriel near to the upper 
left corner of the map is marked with a letter m on the 
right shoulder of the node, which means that the article 
is a meta-analysis. Similarly, we know that the 1998 
article by Hawkey at the top of the 1998 time zone is a 
randomized clinical trial because it is marked as rc.  
The visualization reveals several important clues of 
the evolution of NSAID. The earliest prominent term is 
prostaglandin-synthesis in the 1991 time zone, which is 
the foundation and the early focus of NSAID. The next 
term peaked is h-2 receptor antagonists in 1994. In the 
1999 time zone, terms such as proton pump inhibitors 
and anti-inflammatory drug gastropathy are attached to 
the main stream, highlighting the adverse effects of 
non-selective inhibitors. The term selective-cox-2-
inhibitor is prominent in the 2000 time zone. The term 
cost-effectiveness also appeared in the same time, 
underlying the fact that selective inhibitors are more 
expensive than traditional ones. The 2001 time zone 
contains terms colon-cancer-cells and h-pylori-
infection. More terms related to cox-2-sepcific-
inhibitors and gastrointestinal-safety in 2002. In 2003, 
Alzheimer’s disease emerged strongly (shown in the 
map as s-disease near the top). In 2004, the most 
prominent research front terms are proton pump 
inhibitor and pump inhibitor. Note that this is the 
second peak of proton pump inhibitor; its first peak 
was in 1999. 
 
 
Figure 5 The time-zone view of the evolution of the NSAID literature. The network contains 499 
nodes and 2,018 lines. Clinical evidence is marked according to its publication type. 
6. Discussions and Conclusions 
From these prominent thematic terms we can form a 
number of hypotheses of what happed in the literature as the 
field of NSAID evolved over the past decade. As the first 
step, we want to establish that there are evidently a few lines 
of research running in parallel in NSAID. The next step is to 
verify the role of specific clinical evidence in the process of 
change. 
The most interesting and potentially intriguing 
hypothesis is that the revival of proton pump inhibitor in 
2004 was connected to the increased heart-attack risk found 
in selective inhibitors such as Vioxx. If there is indeed a 
tendency to fall back to the earlier non-selective anti-
inflammatory agents, then the regained attention of proton 
pump inhibitors will make sense because they were co-
prescribed in the past with non-selective inhibitor drugs. 
We found that clinical evidence as a group tends to be 
cited higher than other types of articles in the NSAID 
example. The visualizations have enabled us to identify 
RCTs and meta-analysis in unique positions within the 
network of research front terms and intellectual base articles. 
Meta-analysis in such positions would be the best candidate 
for examining the consensus based on existing evidence. 
RCTs in similar positions would be the strongest evidence 
that must be taken into account when making clinical 
decisions.  
The purpose of the visualization is not to provide direct 
answers to the questions raised. Instead, we intend to 
provide the practitioners of EBM with an alternative tool 
that allows them to identify high-quality clinical evidence in 
the changing literature of medicine more effectively, 
especially in light of the rigorous, recentness, and consensus 
of available clinical evidence. In terms of training and 
education, it is particularly encouraging that the 
visualization appears to portrait a convincing timeline of the 
evolution of NSAID. This approach can be valuable for 
researchers who are preparing systematic reviews of clinical 
evidence by simplifying the search and selection of critical 
evidence to review. Furthermore, the contextual view of how 
existing evidence is cited in the literature provides valuable 
alternative viewpoints for systematic reviews. 
The preliminary results are encouraging because the 
automatic annotation technique provides a harmonic way to 
combine two different sources of evidence, namely the 
citation patterns and the study design types of clinical 
evidence. There is a substantial amount of work to be done 
before it can be used by healthcare educators and 
practitioners. For example, it requires systematic validations 
of detailed findings against existing gold standards. This 
case study also has practical and theoretical implications to 
knowledge domain visualization. Since events such as the 
Merck’s withdraw of Vioxx might fall outside the range of a 
traditional domain analysis, it remains to be done to 
integrate various interrelated components into a fully 
responsive system so that trends detected in the literature of 
medicine and life sciences can be directly connected to 
decision making and other healthcare activities in more 
timely manner.  
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